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ABSTRACT
Cell proliferation and growth are regulated by a complex network of growth factor and growth inhibitor-
initiated signal transduction pathways. The disruption of these signaling pathways through genetic, epi-
genetic, or somatic alterations is a major area of cancer research. Increasing evidence indicates that
oncogenic activation of growth factors and their receptor proteins occur through mutations (oncopro-
teins) that lead to constitutive activation of the signaling pathways, thus providing the grounds for puta-
tive prognostic marker(s) and potential target(s) for treatment of various cancers. Over the past few
years, the study of genomics has revealed the gene expression signatures for many malignancies.
Present communication outlines literature survey on genomic molecular markers of breast, lung, and
prostate cancers. Reassuringly, the dominant genomic markers of these malignancies include oncopro-
teins and provide a support for their clinical validity as cancer targets. More specifically, this article
reviews recent advances in clinical targeting of these malignancies by two types of growth factor/recep-
tors, namely transforming growth factor-b (TGF-b), and EGFR subfamily of tyrosine kinase receptors
including ErbB2. Overexpression of these proteins has been demonstrated in patients with cancer pro-
gression and correlated with poor prognosis, increased frequency of metastasis and death. In addition,
EGFR and ErbB2 inhibitors have been used in targeted therapy of lung and breast cancer, respectively.
Recent investigations of lung cancer have uncovered that EGFR inhibitors have their greatest effect in
patients with EGFR somatic mutations thus raising a possibility that EGFR mutations may be a molecu-
lar predictors of sensitivity to EGFR inhibitors.
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INTRODUCTION 
C
ancer is a challenging disease for medicine due to a genetic heterogeneity that ulti-
mately dictates clinical behavior. Over the past few years, the study of genomics has
embarked on developing gene expression-based classifications for tumors - an initiative
that promises to revolutionize cancer medicine (1). Genomic classifications from microar-
rays have now been developed for many malignancies, including breast, lung, prostate,
brain, ovary, gastric, leukemia, and lymphomas. It is of interest to note that, in breast (2),
lung (3) and prostate (4) cancer, the major signatures that appear include oncogenes,
oncoproteins, and other conventional biomarkers obtained from existing paradigms (2-4). 
Cell proliferation and growth are regulated by a complex network of growth factor- and
growth inhibitor-initated signal transduction pathways. The disruption of these signaling
pathways, through genetic, epigenetic, or somatic alterations, is a major area of cancer
research. Increasing evidence indicates that oncogenic activation of growth factors and
their receptor proteins occur through mutations (oncoproteins) that lead to constitutive acti-
vation of the signaling pathways (5), thus providing the grounds for putative prognostic
marker(s) and potential target(s) for treatment of various cancers. Present communication
focuses specifically on aberrations of growth factor/proteins (oncoproteins) and their role
in clinical and experimental oncology. In an effort to organize this text, an attempt was not
made to cover every growth factor investigated as a potential cancer biomarker. Rather, this
presentation summarizes state-of-the art for TGF-b and EGFR, the growth factor/receptors
that are being extensively investigated for potential clinical applicability. In addition, signifi-
cant presence of these oncoproteins in the shortlists of genomic molecular markers of
breast, lung, and prostate cancer has been observed thus supporting their clinical validity
as cancer targets (2-4).
Genomic molecular markers for cancer diagnostics
The most comprehensive genomic signatures have been uncovered in breast cancer (BC)
where significant biological and clinical molecular classifications have been made using
several different microarray platforms and with tumors of different stages (2). Table 1
reveals genomic classification of BC based on the appearance of two major clusters desig-
nated as luminal and basal with respective shortlists of the most significant overexpressed
genes. The luminal class of tumors, exhibiting a molecular signature resembling the lumi-
nal cells of the breast duct, has been further subdivided into two different luminal clusters
with either a favorable prognosis (luminal A) or a less favorable prognosis (luminal B/C).
The basal class of tumors, on the other hand, shared genes expressed by basal myoepthe-
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lial cells (2). The benefit of providing general biological classifications, such as luminal and
basal, is to avoid confusion from naming a tumor class after a single marker that is promis-
cuous in expression.
To date, the ERbB2 class presented in Table 1 is not as robustly defined by genomics as
the other groups and the nomenclature is somewhat inconsistent. Amplification of the
17q21 region and expression of the ERbB2 gene is currently the best indicator for this group
of tumors (2). Reassuringly, as illustrated in Table 1, the dominant biological features iden-
tified by genomics are consistent with tumor classification already clinically used for risk
stratification. Corresponding markers routinely used in BC diagnostics are two hormonal
receptors (ER and PR) and oncoprotein ErbB2 (also known as HER-2/neu). The pres-
ence/absence of these proteins, commonly scored using immunohistochemistry, currently
forms the basis of a rudimentary molecular classification system including: hormonal
receptor-positive, hormonal receptor-negative, and ERbB2-positive tumors (Table 1). These
classes have been integrated into the diagnosis and treatment of BC patients and help strat-
ify the risk of recurrence. 
Shortlists of the most significantly expressed genes versus conventional prognostic mark-
ers for lung (3) and prostate (4) cancer are illustrated in Table 2. Taken together, the
described data (Table 1,2) demonstrate that phenotypic changes in carcinogenesis are
associated with altered expression levels of multiple genes. Thus, the focus on a single
gene as a disease marker is almost futile when compared to the use of multiple molecular
markers accessible through genomics. In this context, the remaining part of this presenta-
tion will focus on oncoproteins, including TGF-b and EGFR, and their complementary role
in a putative panel of multiple molecular markers to be used in cancer diagnostics.
Why is TGF-b intriguing as a cancer target?
Significant progress has been made in the last decade by many investigators to identify
aberration of transforming growth factor-b (TGF-b) in cancer pathology (6). This growth
factor is intriguing due to its numerous and often opposing cellular functions. It acts as a
tumor suppressor and a tumor promoter, as an inhibitor and stimulator of cellular prolifer-
ation, apoptosis, and angiogenesis. The TGF-b signaling pathway’s elucidation has shown
it to be very complex and involves a TGF-b ligand, three types of TGF-b receptors (TbRI,
TbRII, and TbRIII) and four TGF-b intracellular transducers (Smad 2,3,4,and 7). Many sci-
entists (6,7), including ourselves (8-14), have postulated that members of the TGF-b sig-
naling pathway may be good candidates for prognostic or predictive markers for cancer
patients.  With the discovery that TGF-b was a potent growth inhibitor of epithelial cells, and
the identification of inactivating mutations within the TGF-b signaling pathway in solid
tumors, it became clear that TGF-b signaling is a tumor suppressor pathway for early
stages of cancer. However, in advanced cancer stages overexpression of TGF-b has been
observed and it has been associated with poor patients’ prognosis and increased frequen-
cy of metastasis (6). Increased TGF-b levels are found in plasma of patients with invasive
prostate and breast cancer (7), and in serum of patients with colorectal cancer, hepatocel-
lular carcinoma, lung cancer, and metastatic melanoma (6). We have previously deter-
mined, for the first time, significantly elevated plasma TGF-b levels in prostate cancer (PC)
patients with invasive disease (9). These findings have lead us to propose that plasma TGF-
b concentration may be a new tumor marker attributed to the presence of invasive PC cells
that may be used in the prognosis of PC (9). Subsequently, confirmed by many laborato-
ries, this marker has been proposed as one of the components of PC diagnostic multiplex
panel. Indeed, a biomarker panel containing PSA, TGF-b, and IL6SR has been recently uti-
lized to develop a prostate cancer nomogram to predict the disease regression after radical
prostatectomy (15). By extending this line of research to breast cancer, we have recently
confirmed and extended the evidence for a significantly elevated plasma TGF-b levels in
advanced BC patients with a poor prognosis (12). Moreover, we have observed that in post-
menopausal patients this elevation was associated with ER/PR negative status and
decreased probability of survival (14). Although the complete molecular mechanism of
action and the role of TGF-b in cancer progression still remains to be elucidated, current
findings suggest that selective cancer-specific mutations are responsible for the observed
overexpression in various malignancies. Loss of TbRII expression and selective mutations
of T￿RII have been observed in renal and colon cancer, respectively (6). In addition, a TGF-
b polymorphism (T29-C) has been associated with higher serum TGF-b levels and with an
increased risk in advanced breast cancer (16). In terms of targeted therapy, attempts to
block the effects of excessive TGF-b activity have been tried involving agents that inhibit
TGF-b binding to its receptors. They include natural TGF-b inhibitors (e.g., decorin), neu-
tralizing TGF-b antibodies, soluble extracellular domains of the receptors, and small mole-
cule inhibitors of TbRI kinase activity (6). Further research, in this rapidly progressing field
will likely lead to new diagnostic marker(s) and therapeutic strategies.
EGFR AS A CLINICAL TARGET IN CANCER
The most frequently implicated receptors and growth factors in human cancer are members
of the EGFR subfamily of tyrosine kinase receptors (2,3). The type I subfamily includes
EGFR (ErbB1), HER-2/neu (ErbB2), HER-3 (ErbB3), and HER-4 (ErbB4). These receptors
share a common molecular architecture including a large glycosylated extracellular ligand-
binding domain, a single hydrophobic transmembrane domain, and a cytoplasmic tyrosine
kinase domain (17). In breast cancer, ErbB2 (also known as HER-2 or neu) is overex-
pressed in 20-30% of all BC patients and is associated with a high risk of relapse and death
(18). One of the main reasons for the clinical utility of the tissue measurement of ErbB-2 is
the selection of patients with invasive BC for trastuzumab (Herceptin) therapy. This agent is
a humanized monoclonal antibody that has specificity for extracellular domain of the recep-
tor (18). In lung cancer, overexpression of EGFR has been reported to be present in over
50% of cases in several series (19). Moreover, EGFR has been used as a therapeutic tar-
get in clinical trials involving the tyrosine kinase inhibitors (TKIs), including Gefitinb and
Erlotinib that inhibit the intracellular tyrosine kinase domain by interfering with autophos-
phorylation by adenosine triphosphate (ATP). Initially, therapeutic inhibition of EGFR by TKIs
was demonstrated in only 10% to 20% of all lung cancer patients (20). Several investiga-
Table 1. Comparative classification of clinical breast cancer types based on genomic molecular mark-
ers versus conventional prognostic markers as described by Robinson et al (2)
Table 2. Shortlist of genomic molecular markers versus clinically used conventional biomarkers of
lung and prostate cancer as described by Kaminki et al (3) and Welsh et al (4), respectively
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tions over the last two years have uncovered that mutations in EGFR underlie the sensitiv-
ity to EGFR inhibitors. These mutations are somatic and found only in lung tumor tissues
(19). They have been identified only in the tyrosine kinase domain encoded by exons 18 to
24 of the EGFR gene and include missense mutations with changes in the amino acids in
exons 18 and 21, several overlapping deletions in exon 19, and small in-frame insertions in
exon 20. The most common EGFR mutations include the exon 19 deletion (61%) and the
missense mutation (24%). Although the mechanism by which the mutations in the EGFR
tyrosine kinase domain render the receptor more sensitive to the effects TKIs is not yet
defined, these findings suggest that EGFR mutations may serve as molecular predictors of
sensitivity to EGFR inhibitors. Currently, EGFR mutation detection is becoming clinically
available and is being incorporated into clinical treatment decisions and into the design of
ongoing clinical trials (19). Furthermore, despite the remarkable initial success in the sys-
temic treatment by TKIs in advanced lung cancer patients with EGFR mutations, a sub-
stantial proportion of these patients will ultimately develop disease regression. The mech-
anism underlying such acquired resistance to EGFR TKIs is beginning to be understood
involving a common secondary mutation, a substitution of methionine for threonine at posi-
tion 790 (T790M), only in the recurrent tumor specimens. The bulkier methionine residue
in the T790M mutation results in a steric hindrance that likely prevents TKIs from inhibiting
EGFR phosphorylation (19). These findings should spur the development of second-gener-
ation EGFR inhibitors and guide the use of such agents to patients with this specific mech-
anism of acquired resistance.     
CONCLUSION
The genetic signatures presently available using microarrays indicate that the expression
profiles of a relatively small number of cancer-related genes may provide a molecular
means of identifying clinically important molecular targets and biomarkers not identified
before. Experimental approaches are required to combine data obtained from existing par-
adigms and those of tumor profiling by genomic analysis to link complementary aspects of
cancer biology.  The overexpression or increased function of many oncogenes, including
c-Myc, mutated K-ras, EGFR, TGF-b, etc., has been implicated in the pathology of various
cancers. Reassuringly, the gene expression signatures identified by genomics and pro-
teomics include TGF-b and EGFR oncoproteins thus provide a support for their clinical
validity as cancer targets.
Although TGF-b and members of the TGF-b signaling pathway are being evaluated as prog-
nostic or predictive markers for cancer patients, a diagnostic role of TGF-b has not been
established yet. Ongoing advances in understanding the TGF-b signaling pathway will
enable targeting of this pathway for the chemoprevention and treatment of human cancer.
On the other hand, new mutations of EGFR signaling pathway responsible for both sensi-
tivity and resistance to EGFR inhibitors of lung cancer patients are being discovered on an
ongoing basis. This topic is clearly interesting and important subject of further investiga-
tions and requires demonstration of the clinical significance of different EGFR mutations.
Furthermore, the methods currently used to detect different EGFR mutations by DNA
sequencing are time consuming, complicated and costly. While microarray technologies
are emerging, validation of these techniques will be required. The combined information
revealed by these studies will identify molecular determinants involved in cancer diagnosis,
prediction of clinical outcome, and response to therapeutic intervention.
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